Cite
HARVARD Citation
Xie, M. et al. (n.d.). 2595 Phase II study of pazopanib as second-line treatment aftersunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial. European journal of cancer. pp. S510-. [Online].